It is with great pleasure that we present another really good year of growth. The figures for the full year 2022 add up to an increase in sales equivalent to 30% in organic growth. In total, sales amount to approximately SEK 122 million. Our ETEC vaccine candidate, ETVAX, is about to enter phase 3.
All participants have received the third and final vaccination dose in our large randomized, placebo-controlled, and double-blind phase 2b study in The Gambia. The study includes 4 936 children aged 6-18 months. The overall goal of the study is to investigate the efficacy against moderate to severe diarrhea caused by ETEC.
The first child has been vaccinated in The Gambia with the company's ETEC vaccine candidate, ETVAX®. It is a randomised, placebo-controlled, and double-blind phase IIb study. The study will include about 5,000 children aged 6-23 months. The overall goal of the study is to investigate the protective effect against moderate to severe diarrhoea caused by ETEC over a 1- to 2-year period.
In record time we completed a phase IIB randomized, double-blind, placebo-controlled trial in Finnish travellers going to West Africa. In total 743 travellers spent a fortnight in Benin. Half of the group were given the ETEC vaccine candidate, ETVAX®, and the other half placebo. The aim of the study was to evaluate safety and estimate the protective efficacy in a naive population.
Vi utvecklar det första vaccinet i världen mot diarré orsakad av ETEC för att skydda både barn och vuxna i endemiska länder och resenärer till högriskdestinationer.
Vi distribuerar ett brett sortiment av biologiska specialistläkemedel med fokus på vacciner och immunglobuliner.
www.scandinavianbiopharma.se
Vår information på mynewsdesk riktar sig till journalister och media.
Industrivägen 1, vån 4
171 48 Solna
Sverige